These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 3551180

  • 21. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
    Monreal M, Lafoz E, Olive A, del Rio L, Vedia C.
    Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649
    [Abstract] [Full Text] [Related]

  • 22. Low molecular weight heparin prevention of post-operative deep vein thrombosis in vascular surgery.
    Speziale F, Verardi S, Taurino M, Nicolini G, Rizzo L, Fiorani P, Palazzini E.
    Pharmatherapeutica; 1988 Jan; 5(4):261-8. PubMed ID: 3174726
    [Abstract] [Full Text] [Related]

  • 23. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF, Neuhart E.
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [Abstract] [Full Text] [Related]

  • 24. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin).
    Ockelford PA, Patterson J, Johns AS.
    Thromb Haemost; 1989 Dec 29; 62(4):1046-9. PubMed ID: 2559484
    [Abstract] [Full Text] [Related]

  • 25. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
    Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, PEGASUS investigators.
    Br J Surg; 2005 Oct 29; 92(10):1212-20. PubMed ID: 16175516
    [Abstract] [Full Text] [Related]

  • 26. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B.
    Thromb Haemost; 1998 Jun 29; 79(6):1162-5. PubMed ID: 9657442
    [Abstract] [Full Text] [Related]

  • 27. Low molecular weight heparin (Logiparin) as thromboprophylaxis in elective abdominal surgery. A dose finding study.
    Hauch O, Jørgensen LN, Kølle TR, Nerstrøm H, Schebye O, Wille-Jørgensen P, Ostergaard P.
    Acta Chir Scand Suppl; 1988 Jun 29; 543():90-5. PubMed ID: 2847464
    [Abstract] [Full Text] [Related]

  • 28. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P, Behounek J, Skoták M, Nevsímal L.
    Acta Chir Orthop Traumatol Cech; 2004 Jun 29; 71(4):237-44. PubMed ID: 15456102
    [Abstract] [Full Text] [Related]

  • 29. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M.
    Arch Intern Med; 1994 Jan 10; 154(1):49-56. PubMed ID: 8267489
    [Abstract] [Full Text] [Related]

  • 30. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group.
    Harenberg J, Roebruck P, Heene DL.
    Haemostasis; 1996 Jan 10; 26(3):127-39. PubMed ID: 8738587
    [Abstract] [Full Text] [Related]

  • 31. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S, ASPIRE Investigators.
    Circulation; 2005 Mar 22; 111(11):1390-7. PubMed ID: 15781750
    [Abstract] [Full Text] [Related]

  • 32. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov 22; 20(21):1553-62. PubMed ID: 10529323
    [Abstract] [Full Text] [Related]

  • 33. Delivery of low molecular weight heparin for prophylaxis against deep vein thrombosis using a novel, needle-less injection device (J-Tip).
    Hollingsworth SJ, Hoque K, Linnard D, Corry DG, Barker SG.
    Ann R Coll Surg Engl; 2000 Nov 22; 82(6):428-31. PubMed ID: 11103165
    [Abstract] [Full Text] [Related]

  • 34. Low molecular weight heparin: a critical analysis of clinical trials.
    Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW.
    Pharmacol Rev; 1994 Mar 22; 46(1):89-109. PubMed ID: 8190751
    [Abstract] [Full Text] [Related]

  • 35. Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications.
    Bergqvist D, Burmark US, Frisell J, Hallböök T, Lindblad B, Risberg B, Törngren S, Wallin G.
    Haemostasis; 1986 Mar 22; 16 Suppl 2():11-8. PubMed ID: 3744131
    [Abstract] [Full Text] [Related]

  • 36. Pharmacology of low molecular weight heparins.
    Harenberg J.
    Semin Thromb Hemost; 1990 Oct 22; 16 Suppl():12-8. PubMed ID: 1962899
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study.
    Kakkar VV, Murray WJ.
    Br J Surg; 1985 Oct 22; 72(10):786-91. PubMed ID: 3899240
    [Abstract] [Full Text] [Related]

  • 38. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
    Lane DA, Ireland H, Flynn A, Anastassiades E, Curtis JR.
    Nephrol Dial Transplant; 1986 Oct 22; 1(3):179-87. PubMed ID: 2955253
    [Abstract] [Full Text] [Related]

  • 39. Thrombosis prophylaxis in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7,500 and 2,500 anti-Xa IU/day).
    Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG.
    Haemostasis; 1986 Oct 22; 16 Suppl 2():69-70. PubMed ID: 3527887
    [No Abstract] [Full Text] [Related]

  • 40. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy.
    Omri A, Delaloye JF, Andersen H, Bachmann F.
    Thromb Haemost; 1989 Feb 28; 61(1):55-6. PubMed ID: 2546279
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.